N ε-(γ-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease

Journal of Neurochemistry

Volumn 79, Issue 5, 2001, Pages 1109-1112

  Jeitner, Thomas M ^a,b   Bogdanov, Mikhail B ^a   Matson, Wayne R ^c   Daikhin, Yevgeny ^d   Yudkoff, Marc ^d   Folk, John E ^e   Steinman, Lawrence ^f   Browne, Susan E ^a   Flint Beal, M ^a   Blass, John P ^a,b   Cooper, Arthur J L ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^c Chelmsford MA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cerebrospinal fluid; Huntington's disease; N ( L Glutamyl) L lysine; Neurodegenerative diseases; Transglutaminases

Indexed keywords

HUNTINGTIN; LYSINE DERIVATIVE; N EPSILON (GAMMA GLUTAMYL)LYSINE; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG; DIPEPTIDE; EPSILON (GAMMA GLUTAMYL) LYSINE; EPSILON-(GAMMA-GLUTAMYL)-LYSINE; PHTHALALDEHYDE;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; PRIORITY JOURNAL; ADULT; CEREBROSPINAL FLUID; CHEMISTRY; ELECTROCHEMISTRY; FEMALE; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MALE; METABOLISM;

ADULT; CHROMATOGRAPHY, LIQUID; DIPEPTIDES; ELECTROCHEMISTRY; FEMALE; HUMAN; HUNTINGTON DISEASE; MALE; O-PHTHALALDEHYDE; RADIOISOTOPE DILUTION TECHNIQUE; SUPPORT, U.S. GOV'T, P.H.S.; TRANSGLUTAMINASES;

EID: 0034747325     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00673.x     Document Type: Article

References (30)

1. Huntington's disease, energy, and excitotoxicity
2. Energetics in the pathogenesis of neurodegenerative diseases
3. Trinucleotide repeat length and clinical progression in Huntington's disease
4. Polyglutamine domains are substrates of tissue transglutaminase. Does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?
5. Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and α-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length
6. n-expansion diseases with special reference to the role of tissue transglutaminase and selective vulnerability
7. n expansion diseases
8. n-expansion diseases?
9. Spectrophotometric assays for 1-lysine α-oxidase and γ-glutamylamine cyclotransferase
10. Formation of intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
11. An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue microdialysis perfusates
12. Cysteamine and cystamine
13. γ-glutamylamine cyclotransferase: Specificity toward ε-(l-γ-glutamyl)-l-lysine and related compounds
14. The ε-(γ-glutamyl) lysine cross-link and the catalytic role of transglutaminases
15. Neurotoxicity of β-amyloid and prion peptides
16. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: A possible mechanism contributing to CAG-triplet diseases
17. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome
18. Simultaneous profile analysis of plasma amino and organic acids by capillary gas chromatography
19. Peptides containing glutamine repeats are substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous system
20. Transglutaminase action imitates Huntington's disease: Selective polymerization of huntingtin containing polyglutamine
21. Transglutaminase aggregates huntingtin into non-amyloidogenic polymers and its enzymatic activity is increased in Huntington's disease brain
22. Cystamine, a competitor for transglutaminase, slows the progression of Huntington's disease in a transgenic mouse model without altering formation of nuclear inclusions
23. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease
24. Huntington's disease
25. Tissue transglutaminase is increased in Huntington's disease brain
26. 'Tissue' transglutaminase in cell death: A downstream or a multifunctional upstream effector?
27. Stable isotope tracer analysis by GC-MS, including quantification of isotopomer effects
28. The γ-glutamyl cycle in the choroid plexus: Its possible function in amino acid transport
29. Homozygotes for Huntington's disease
30. Transglutaminase catalyzed cross-links in intranuclear inclusions